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The use of biomarkers within the procedures of the Committee of Orphan Medicinal Products (COMP) of the European
Medicines Agency (EMA) is discussed herein. The applications for Orphan Medicinal Product designation in the EU are
evaluated at two stages. At the time of orphan designation application, the file undergoes an assessment to establish
whether the proposed condition is a distinct and serious condition affecting not more than 5 in 10,000 people in the
EU, and whether the product is plausible as a therapy for that condition. In cases where therapies already exist, the
significant benefit of the candidate product over existing therapies is also evaluated. The orphan criteria are reassessed
at the time of marketing authorisation, so that marketing exclusivity for the product in the orphan medical condition
can be granted. Within this context, biomarkers have been used in submissions in order to define an orphan condition
and to justify that the criteria for orphan designation are met. The current work discusses specific examples from the
experience of the COMP, where biomarkers have played a decisive role. Importantly, it identifies the proposal of
sub-sets of non-rare conditions based on biomarkers as a challenging issue in the evaluation of applications. In
particular two specific requirements for the candidate orphan medicines in relation to the biomarker-based subsets are
highlighted: the “plausible link to the condition” and the “exclusion of effects outside the subset”.
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The use of biomarkers, which are specific for medical
conditions, is envisioned to accelerate the research and
development and increase the success rate of pharma-
ceutical products [1]. This approach is characterised by
increased specificity of therapeutic targets and delinea-
tion of specific populations for which a medicinal prod-
uct has improved efficacy or improved safety. In the
field of developing medicines in conditions that occur so
rarely that pharmaceutical industry generally believe that
the return on investment is not optimal (the so-called
orphan medicinal products), this approach may conse-
quently lead to an enrichment of the limited armament-
arium to diagnose prevent or treat those conditions.
The Committee of Orphan Medicinal Product (COMP)
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stated.faced challenges when evaluating submissions for orphan
designation. The COMP has been assessing the use of bio-
markers by sponsors of candidate orphan products in
three main areas:
 to define the distinct medical condition or a valid
sub-set for the designation (orphan condition as
described in guideline ENTR6283/Rev03) [2]
 to justify the intention to diagnose, prevent or treat
a condition with a product, (as per the provisions of
Article 3(1)(a) of Regulation (EC) No 141/2000 [3])
 to determine significant benefit (as per Article 3(1)(b)
of Regulation (EC) No 141/2000 [3])
In recent years, concomitantly with an increase in the
number of applications [4], the conditions proposed for
designation are expanding to new areas and becoming
increasingly complex, while candidate products may tar-
get specific populations or subsets within broader distinct
medical entities. This has resulted in an accumulation ofLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
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as well as the limitations of biomarker use for regulatory
purposes in the field of orphan medicinal products.
This work was produced to present the current per-
spectives regarding the use of biomarkers in submissions
for orphan designation. It is based on an internal EMA-
COMP reflection paper produced by an ad-hoc bio-
markers working group composed of Members of the
COMP and its objectives include:
 Examination of the role of biomarkers in
submissions from sponsors seeking Orphan
Medicinal Product Designation.
 Presentation and discussion of past submissions to the
COMP where biomarkers were used by sponsors in
their request for an Orphan Medicinal Product
Designation
 Reflection on when and how the COMP has taken
biomarkers into consideration when assessing
medicinal products.
Table 1 highlights the glossary used in this paper.
Use of biomarkers in sub-setting and defining a valid
sub-set for the purpose of orphan designation
The COMP follows certain guidance documents to assist
it in evaluating submissions for Orphan Medicinal Prod-
uct Designation. One of the principle guidance documents
of this nature is the section on General requirements and
Special considerations for the description of the condition
in an application for orphan designation of Guideline
ENTR 6283/00 Rev.03 [2]. Key concepts pertaining to the
proposed condition for designation are reproduced from
this guideline in the Table 2.
Typically only recognised distinct medical entities are
considered as valid conditions for designation, while
sub-sets are only exceptionally considered. Proposals of
subsets based on biomarkers are scrutinized inter alia
with regards to the following conditions:
 the subset proposed should fall entirely within a
distinct medical condition (therefore not spanningTable 1 Glossary used in this paper
Biomarker: A characteristic that is objectively measured
processes, or pharmacologic responses to a t
Surrogate endpoints: A biomarker intended to substitute for a clin
(or harm, or lack of benefit) based on epidem
Condition: Any deviation(s) from the normal structure o
symptoms (typically recognized distinct disea
Orphan Condition: the condition as defined above that meets t
ENTR/6283/00 Rev3) [2].
Personalised Medicine: A medicine targeted to individual patients, bpopulations affected by more than one distinct
medical entity)
 there should be a clear delineation of the subset
from the entire of the population (in the context of
this paper: a well-defined biomarker)
 the subset should have a “plausible link to the
condition” and
 the subset should be “closely linked to the
pharmacological action of the medicinal product in
such a way that the absence of these characteristics
will render the product ineffective in the rest of the
larger population with the same condition”
In particular with regards to the requirement of “plaus-
ible link to the condition”, this is to be interpreted as a limi-
tation to the category of subsets: the subset may not refer
to features that do not pertain directly to the condition or
disease, thereby limiting the never-ending potential sub-
setting based e.g. on immunological or genomic features of
the individual patients and not of the underlying disease.
The requirement of “exclusion of effects outside the pro-
posed subset” is equally important, and involves a vigorous
assessment of the pharmacodynamics of the product to
ensure that in the excluded population (in the context of
this paper the population outside the biomarker-defined
subset) the product will not have any favourable pharma-
codynamic effect. To illustrate these limitations in the use
of biomarker for the purpose of proposing subsets as valid
conditions for designation, specific examples are presented
below. These were selected on the basis of clarity and use-
fulness for the points discussed in this paper.
The limitations of biomarker use in defining acceptable
indications for orphan designation
There is a number of unsuccessful cases of orphan appli-
cations evaluated by the COMP, which involved bio-
markers used to define specific orphan conditions. The
justification of “a plausible link to the proposed orphan
condition” and the “exclusion of effects” in the wider
non-orphan population have proven to be the key draw-
backs in these applications. Both of these points are il-
lustrated in the actual case studies elaborated below. Asand evaluated as an indicator of normal biologic processes, pathogenic
herapeutic intervention [5].
ical endpoint. A surrogate endpoint is expected to predict clinical benefit
iologic, therapeutic, pathophysiologic or other scientific evidence [5].
r function of the body, as manifested by a characteristic set of signs and
se or a syndrome) (guideline ENTR/6283/00 Rev3) [2].
he criteria defined in Art.3 of Regulation (EC) No 141/2000 (guideline
ased on their genetic characteristics [6].
Table 2 General requirements and special considerations for the description of the condition in an application for
orphan designation reproduced from the guideline ENTR 6283/00 Rev 03
General requirements
(a) The characteristics defining a distinct condition should determine a group of patients in whom development of a medicinal product is plausible,
based on the pathogenesis of the condition and pharmacodynamic evidence and assumptions.
(b) Recognised distinct medical entities would generally be considered as valid conditions. Such entities would generally be defined in terms of
their specific characteristics, e.g. pathophysiological, histopathological, clinical characteristics.
(c) Different degrees of severity or stages of a disease would generally not be considered as distinct conditions.
The fact that a subset of patients exists in whom the medicinal product is expected to show a favourable benefit/risk (as defined in the proposed
therapeutic indication) would generally not be sufficient to define a distinct condition.
Special considerations
(a) Considering the above general requirements, convincing arguments would need to be presented to justify the medical plausibility of any
proposed subset and the rationale for excluding the larger population. A subset of a disease which, when considered as a whole, has a
prevalence greater than 5 in 10,000, could be considered a valid condition if patients in that subset present distinct and unique evaluable
characteristic(s) with a plausible link to the condition and if such characteristics are essential for the medicinal product to carry out its action. In
particular, the pathophysiological characteristics associated with this subset should be closely linked to the pharmacological action of the
medicinal product in such a way that the absence of these characteristics will render the product ineffective in the rest of the population.
(b) Patients may be affected by more than one condition. Generally the intersection of two (or more) concomitant conditions would not be
considered as a valid condition. However, it could be acceptable, if such intersection resulted in a certain new evaluable characteristic essential
for the pharmacological effect and the medical outcome.
(c) Exceptionally, the need for a particular treatment modality (regardless of underlying diseases) can be considered as a valid criterion to define a
distinct condition.
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the final opinion from the COMP, the detailed aspects of
confidential nature are not discussed in detail.
Limitations based on the “plausible link to the condition”
The first example pertains to a case discussed in 2013,
involving a therapy proposed for treatment of non-
small-cell lung cancer in patients expressing HLA-A2.
The Committee considered that in particular the
“plausible link to the condition” (Table 2) was not met,
even though the “exclusion of effects” could be consid-
ered acceptable. It was agreed that HLA-A2 pertained to
the immune system of an individual and was not a spe-
cific characteristic of a distinct medical condition for
which the proposed product is applied for designation.
The biomarker in this case was focusing not on the con-
dition but on the individual patient characteristics: the
COMP was of the opinion that patients expressing
HLA-A2 were actually sub-setted based on their im-
mune system status and the biomarker did not consti-
tute a specific distinct form of non-small-cell lung
cancer that could define an orphan condition. The popu-
lation of non-small-cell lung cancer expressing HLA-A2
was not considered acceptable as an orphan indication.
Limitations based on the “exclusion of effects”
Two unsuccessful applications are discussed herein, one
of which reached the point of formal adoption of a nega-
tive opinion that has been made public.
a. In the first case discussed in 2012, a product was
proposed for treatment of P-gp positive breastcancer. The sponsor was proposing that P-gp positive
breast cancer could be considered a distinct medical
condition under the orphan legislation as this breast
cancer population is multidrug resistant due to
clinically relevant high level of P-gp. The sponsor in
the application further clarified that the targeted
population covers only 25% of P-gp positive breast
cancers, as this is the proportion they expected to be
multidrug resistant. The COMP noted that P-gp may
be found in close to 100% of breast cancer patients,
and that the product could have an effect in a much
larger population group than the specific subset
proposed by the sponsor as being a distinct orphan
medical condition. The COMP considered the 25%
cut-off point to be arbitrary and unsupported by
current clinical evidence to support the claim that this
was a distinct orphan medical condition. The
Committee concluded that the condition applied for
(treatment of P-gp positive breast cancer) is not a
valid subset for orphan designation.
b. Another interesting case was discussed in 2011,
pertaining to the application of a product for the
treatment of ALK-positive non-small cell lung cancer.
In that case the sponsor was proposing that the subset
of “ALK-positive non small cell lung cancer” could be
considered as a distinct orphan medical condition.
This subset is characterised by a gene fusion between
the anaplastic lymphoma kinase (ALK) gene and ech-
inoderm microtubule-associated protein-like 4
(EML4), leading to expression of aberrant ALK recep-
tors on the malignant cells. The proposed product for
designation was claimed to be a specific inhibitor of
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noted that this product was also an inhibitor of the
c-Met/HGFR receptor tyrosine kinase. The mixed na-
ture of product actions established the basis that the
proposed sub-setting was not justified since some
effects may be anticipated in patients not bearing
mutations or ALK overexpression.
Use of biomarkers in the justification of medical
plausibility and significant benefit at orphan designation
As per article 3 of Regulation (EC) No. 141/2000 the
sponsor has to establish that the product is “intended
for the diagnosis prevention or treatment” of a condi-
tion. This intention to diagnose, prevent or treat is ex-
amined under the broader term of “medical plausibility”
in the proceedings of the COMP, and the relevant guide-
lines [2].
In addition, significant benefit in Article 3(1)(b) of
Regulation (EC) No. 141/2000 requires that in the case
where a satisfactory method of diagnosis, prevention or
treatment of the condition exists, the sponsor has to es-
tablish the medicinal product will be of significant bene-
fit to those affected by the condition.
Significant benefit (SB) is further defined in Article 3
of Commission regulation EC 847/2000 as “… a clinic-
ally relevant advantage or a major contribution to pa-
tient care” [7]. As per commission communication on
regulation (EC) No141/2000, “…the justification for sig-
nificant benefit is likely to be made on assumptions of
benefit by the applicant. In all cases the Committee on
Orphan Medicinal Products (COMP) is required to as-
sess whether or not these assumptions are supported by
available data/evidence supplied by the applicant” [8].
This is also discussed in guideline ENTR/6283/00 Rev 3
section D page 11/13 where it is stated, “…significant
benefit should be based on well justified assumptions.
Assumptions of potential benefit(s) should be plausible
and where possible based on sound pharmacological
principles. Preclinical data and preliminary clinical infor-
mation may be added as supportive evidence. In general
a demonstration of potentially greater efficacy, an im-
proved safety profile, and/or more favourable pharma
cokinetic properties than existing methods may be con-
sidered to support the notion of significant benefit.
Other compliance-promoting features or evidence to
show fewer interactions with food or other medicinal
products, where these are relevant may also be consid-
ered” [2].
In order to justify the rationale for the intention to
prevent, treat or diagnose, and for the justification of a
clinically relevant advantage in case other satisfactory
methods exist, biomarkers have been used as surrogate
endpoints, without major issues with their use having
been identified so far. The sponsor may use them, aslong as it justifies that the models or clinical settings
are relevant for the proposed condition, and that the
endpoints studied are appropriate. A long list of exam-
ples, can be found in the monthly release of the COMP
plenary meeting minutes that are being made public by
the European Medicines Agency since September 2012.
Discussion
In the context of orphan regulatory procedures, the sin-
gle major challenge in biomarker use has been the sub-
setting of broader medical entities in order to define a
valid orphan condition for designation.
With reference to the guideline on the format and
content of the applications for designation, patients in a
proposed sub-set have to present distinct and unique
pathophysiological, histological, aetiological and clinical
symptoms which are evaluable characteristic(s) with a
plausible link to the proposed orphan condition and the
biomarker characteristics should be essential for the
medicinal product to carry out its action. Consequently
two main requirements in the sub-setting of broader
medical entities for the purpose of proposing orphan
conditions emerge: 1) establishing a plausible link to
the broader sub-setted condition and 2) demonstrating
clearly that the presence or absence of the biomarker
has a one-to-one relationship with the presence or ab-
sence of the drug to execute its pharmacodynamic
activities.
The “plausible link” requirement may be viewed as an
argument against proposing subsets of non-rare condi-
tions in the era of personalized medicine: when the bio-
marker refers not to the condition but to the individual
patient this link is not preserved. At the same time, it
may be viewed as a guardian of evolution of our scien-
tific understanding: when the biomarkers refer to the
condition then the link is confirmed, and this is of par-
ticular importance in cases when biomarkers redefine
the classification of medical entities as our understand-
ing evolves (diagnostic biomarkers). The specific nature
of biomarkers may be associated with particular regula-
tory difficulties. For example, biomarkers used in the
context of receptors on cancer cells, present a particular
challenge as their detection capability may evolve by
further development of newer detection assays. The
tests are in time rendered more specific and sensitive
and could help in identifying populations who will re-
spond more effectively to the therapy but who do not
necessarily represent a distinct patient population under
the definition of the orphan legislation. Another ex-
ample, indicative of the complexity is the tyrosine kin-
ase area: the fact that an applicant for an orphan
designation does not identify cross reactivity with other
targets does not prevent that a wider investigation and
testing of more cell lines or biopsies may eventually
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the volume of the subset compared to the underlying
broader distinct medical entity. These examples illus-
trate the problem of unequivocally setting thresholds
for definitions of acceptable sub-sets based on
biomarkers.
To take the argument a bit further, it is also becom-
ing apparent that our scientific understanding underpin-
ning the usefulness of biomarkers has been changing
and evolving over time. Indicatively in neurofibroma-
tosis with children it was presumed that tamoxifen
should be used if the tumours were oestrogen receptor
positive. But later it appeared that the product was not
working only via the receptor and that also oestrogen
receptor negative patients could benefit. A similar case
seems to be with the KRAS mutation in colorectal can-
cer. Originally it was thought cetuximab would only be
working in wild type KRAS patients but there are some
other studies indicating that at least some KRAS muta-
tion patients will benefit as well.
Lastly, an interesting point is the evolution of the stan-
dards in the proceedings of the COMP, in the context of
the increasing complexity of medicinal products
reviewed and the recent advancements in scientific and
medical research. Compared to the early days of the
Committee, this has crystallised into shifting the focus
from mainly the “exclusion of effects outside the subset”,
to equally examining both the “exclusion of effects” and
the “plausible link” principles with equal impact. This is
clearly reflected in the examples described above.
Conclusions
 Sub-setting of medical entities to define a valid
orphan condition and justification of the criteria for
orphan designation have been the main areas in
which the COMP has used biomarkers and clinical
surrogate endpoints.
 If biomarkers are to be taken into account for the
proposal of a sub-set of a broader distinct medical
entity as a valid condition for designation, a
decisive factor is the “plausible link to the
condition”. The biomarker should not refer, in
that case, to features external to the broader
distinct medical entity.
 In addition, if biomarkers are to be taken into
account for sub-setting, the anticipated presence or
absence of any pharmacodynamic effect, in either
preclinical or clinical settings, is to be justified and
supplemented by a convincing scientific argumentation
and data justifying that the product will not work in
the excluded patients.
 Even though biomarkers can define a valid
sub-set of a condition acceptable for designation,there is still a need to demonstrate medical
plausibility and significant benefit in the defined
condition.
 As per the orphan regulation, at the time of
marketing authorisation the criteria for orphan
designation are reassessed, which also means that
the validity of the used biomarker(s) has to be
proven at that time.
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